Biohaven Pharmaceutical Holding Company Ltd.
BHVN
BHVN was delisted on the 3rd of October, 2022.
249 hedge funds and large institutions have $8B invested in Biohaven Pharmaceutical Holding Company Ltd. in 2021 Q3 according to their latest regulatory filings, with 56 funds opening new positions, 79 increasing their positions, 86 reducing their positions, and 29 closing their positions.
93% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 29
40% more capital invested
Capital invested by funds: $5.7B → $8B (+$2.3B)
27% more call options, than puts
Call options by funds: $96.7M | Put options by funds: $76.2M
12% more funds holding
Funds holding: 223 → 249 (+26)
0% more funds holding in top 10
Funds holding in top 10: 14 → 14 (0)
8% less repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 86
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$64.7M |
| 2 |
Stifel Financial
St. Louis,
Missouri
|
+$53M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$45M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$43.2M |
| 5 |
Holocene Advisors
New York
|
+$35.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$138M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$83.1M |
| 3 |
GCM
Glenview Capital Management
New York
|
-$41.2M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$40.5M |
| 5 |
AG
Artal Group
Luxembourg
|
-$38.8M |
BHVN Hedge Fund Activity: Q3 2021 in Review
249 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q3 2021, worth a combined $8B — up 40% from $5.7B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new BHVN positions and 29 closed out — a net gain of 27 holders — while 79 added to existing stakes and 86 trimmed.
The largest buyer was Macquarie Group, adding an estimated $64.7M. The largest seller was Thrivent Financial for Lutherans, exiting entirely with an estimated $138M sold.
- 249 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q3 2021, up from 223 in Q2 2021.
- Funds reported $8B of Biohaven Pharmaceutical Holding Company Ltd. stock for Q3 2021, up 40% quarter-over-quarter.
- 56 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q3 2021 and 29 closed out, a net change of +27 holders.
- The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q3 2021 was Macquarie Group, an estimated $64.7M added.
- The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q3 2021 was Thrivent Financial for Lutherans, an estimated $138M sold.
Based on aggregated 13F filings for Q3 2021.